(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Anthony Joshua's driver charged over Nigeria crash that killed two - 2US students studying housing, health outcomes and sustainability win 2026 Rhodes scholarships
- 35 Must-Attempt Fascinating Dishes from Around the World
- 4BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet
- 5Which Store is Your Decision ?
- Jesse Jackson hospitalized, under observation for a neurodegenerative condition
- The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- Geomagnetic storm grounds launch of Mars space weather satellites
- What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
- Ober Gabelhorn glacier reveals remains of man missing for over three decades
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- Why do people have baby teeth and adult teeth?
- 5 Fundamental Ways to employ a Criminal Legal counselor
- Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart?
